| 23 | 9 | 187 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:探究厄贝沙坦联合美托洛尔对慢性心衰患者的临床疗效和血清hs-CRP、NT-proBNP水平的影响。方法:选取2016年6月-2019年6月于我院医治的慢性心衰患者120例作为研究对象,完全随机分为对照组(60例)、治疗组(60例),对照组基础心脏病的治疗、强心、利尿等药物治疗,治疗组患者在对照组基础上给予厄贝沙坦联合美托洛尔,观察对比两组的临床疗效有效率、治疗前后两组患者的心功能指标(LVEF、LVEDD、LVESD)、血清中超敏C-反应蛋白(hs-CRP)、N末端B型利钠肽原(NT-proBNP)水平。结果:治疗后治疗组患者临床疗效的总体有效率明显高于对照组(P<0.05);治疗后治疗组患者的LVEF明显高于对照组(P<0.05);治疗后治疗组患者的LVEDD、LVESD均显著低于对照组(P<0.05);治疗后两组患者的hs-CRP、NT-proBNP水平均显著下降(P<0.05);治疗后治疗组患者的hs-CRP、NT-proBNP水平显著低于对照组,差异有统计学意义(P<0.05)。结论:厄贝沙坦联合美托洛尔对慢性心衰患者治疗效果显著,能更有效缓解患者的炎症反应,改善患者的心功能,值得临床应用。
Abstract：Objective:To investigate the clinical efficacy of irbesartan combined with metoprolol in patients with heart failure and their impacts on serum levels of high sensitivity C-reactive protein(hs-CRP)and Nterminal B-type natriuretic peptide(NT-proBNP).Methods:A total of 120 patients with chronic heart failure treated in our hospital between June 2016 and June 2019 were randomly divided into control group(n= 60)and treatment group(n= 60). The patients in control group were given supportive care for heart disease,cardiotonic and diuretic agents. The patients in treatment group were given irbesartan combined with metoprolol in addition to the treatments in the control group. The treatment response,cardiac function indexes(LVEF,LVEDD,and LVESD),serum hs-CRP and NT-proBNP levels were compared between the two groups before and after treatment.Results:After treatment,the total rate of response in the treatment group was significantly higher than that in the control group( P< 0. 05). After treatment,the treatment group showed significantly higher LVEF(P<0 05)and lower LVEDD and LVESD( P< 0. 05),compared with the control group( P< 0. 05). After treatment,the both groups showed significantly lower levels of hs-CRP and NT-proBNP compared with baseline,and the levels of hs-CRP and NT-proBNP in the treatment group were significantly lower than those in the control group(P<0 05).Conclusion:Irbesartan combined with metoprolol is effective in treating chronic heart failure in terms of more effective relief of inflammation and improvent in cardiac function of patients,and therefore is worthwhile for use in clinical settings.
[1]胡霜，蔡莉，张川平．美托洛尔联合芪苈强心胶囊治疗慢性心力衰竭的疗效观察[J]．重庆医学，2017,46(5):689-691.
[2]王珺．美托洛尔联合曲美他嗪治疗冠心病合并心衰的疗效及对病人生存质量的影响[J]．中西医结合心血管病电子杂志，2019,7(14):32.
[3] Cannon JA,Shen L,Jhund PS,et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function(I-PRESERVE)trial[J].Eur J Heart Fail.2016 Aug;18(8):1021-31.
[4]吕斌．厄贝沙坦联合螺内酯在慢性心衰中的应用效果及对患者心功能的影响探讨[J]．实用心脑肺血管病杂志，2018,26(S2):15-17.
[5]徐启红．美托洛尔和厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭临床观察[J]．深圳中西医结合杂志，2016,26(5):133-135.
[6]吕斌．厄贝沙坦联合螺内酯在慢性心衰中的应用效果及对患者心功能的影响探讨[J]．实用心脑肺血管病杂志，2018,26(S2):15-17.
[7]肖青荣，饶智英．厄贝沙坦联合螺内酯、美托洛尔在慢性心衰的应用效果及体会[J]．临床医药文献电子杂志，2018,5(32):23+26.
[8] Lymperopoulos A,Aukszi B.Angiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production:Implications for heart failure therapy[J].World J Cardiol. 2017 Mar 26;9(3):200-206.
[9]李爱敏，孙妞妞．厄贝沙坦联合螺内酯对慢性心衰的治疗[J]．齐齐哈尔医学院学报，2014,35(17):2574-2575.
[10]杨永超，程华焱．贝那普利联合厄贝沙坦治疗慢性心衰伴蛋白尿的疗效观察[J]．中国现代应用药学，2012,29(6):560-563.
[11]景国强，杨晓艳．厄贝沙坦联合胺碘酮治疗老年心力衰竭并发心律失常效果及预后分析[J]．临床军医杂志，2018,46(3):351-353
[12]刘晋．美托洛尔联合曲美他嗪治疗老年冠心病心力衰竭效果观察[J]．中国乡村医药，2019,26(4):27-28.
[13]吴晓丽．厄贝沙坦联合美托洛尔联合治疗慢性充血性心衰的临床疗效观察[J]．中西医结合心血管病电子杂志，2018,6(7):54.
[14]周艺．慢性心衰应用美托洛尔前后心功能及血浆脑钠肽水平变化及意义[J]．中西医结合心血管病电子杂志，2019,7(8):102-103.
[15]艾利，殷华，汤华，陈红方，梁思奇，罗文兰．美托洛尔缓释片对老年高血压伴慢性心衰患者的疗效及高敏C-反应蛋白的相关性[J]．中国医药科学，2016,6(8):62-64.
[16]李娟．美托洛尔与厄贝沙坦联合治疗慢性心功能不全的疗效及对血浆NT-proBNP水平的影响[J]．中国卫生工程学，2018,17(2):298-299.
基本信息:
中图分类号:R541.6
引用信息:
[1]苏伟江,赖木乔,王李娟.厄贝沙坦联合美托洛尔对慢性心衰患者的疗效和血清hs-CRP、NT-proBNP水平的影响[J].广州医科大学学报,2019,47(05):17-20.